Tech Company Inital Public Offerings
Candel Therapeutics IPO
On 7/29/2021, Candel Therapeutics completed its IPO
Transaction Overview
Company Name
Announced On
7/29/2021
Transaction Type
IPO
Amount
$72,000,000
Proceeds Purpose
The company said in its S1 filing that the proceeds will fund phase 3 trials for its lead oncolytic virus. About $2.7 million will fund patient enrollment in a brain cancer trial and about $3.7 million will support a phase 3 study in patients with newly diagnosed prostate cancer who are at intermediate or high risk of their disease progressing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
117 Kendrick St. 450
Needham, MA 02494
USA
Needham, MA 02494
USA
Phone
Website
Email Address
Overview
Candel Therapeutics is a Massachusetts based biotechnology company developing our proprietary immuno-oncology platforms, including they are Gene Mediated Cytotoxic Immunotherapy (GMCI�) platform and our rQNestin34.5 platform for the treatment of solid tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Estuardo Aguilar-Cordova
Chief Medical Officer
Laura Aguilar
VP - Bus. Development
Brian Guzik
VP - Bus. Development
Stephen Rocamboli
VP - Manufacturing
Daniel Giroux
VP - R & D
Andrea Manzanera
Browse more venture capital transactions:
Prev: 7/29/2021: Redwood Materials venture capital transaction
Next: 7/29/2021: BioIntelliSense venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs